Acusphere Fights Celgene's Bid For Atty Fees In Patent Row
Specialty pharmaceutical company Acusphere Inc. fought back Tuesday against Celgene Corp.'s bid for attorneys' fees in a patent dispute over anti-tumor drug Abraxane, telling a Massachusetts federal court there was nothing...To view the full article, register now.
Already a subscriber? Click here to view full article